Ghiasvand Hesam, Shamseddin Jebreil, Naghdi Seyran, Biglarian Akbar
Warwick Evidence, Warwick Medical School, University of Warwick, Coventry, UK.
Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Iran J Public Health. 2023 Feb;52(2):399-406. doi: 10.18502/ijph.v52i2.11893.
HIV/AIDS is a leading cause of mortality and morbidity in Low-and-Middle-Income-Countries (LMICs). It might potentially lead to an economic burden on the health system. There is no certainty about the prevalence of HIV/AIDS in Iran. Therefore, we aimed to estimate the cost of illness of HIV/AIDS in Iran.
We applied a societal perspective to capture the direct and indirect costs attributed to HIV/AIDS in Iran. We used data for age-standardized prevalence produced by the country HIV/AIDS Surveillance System for 2018. The study estimated both direct and indirect costs for a hypothetical cohort of the Iranian adult population (here equates to all registered cases with Surveillance System). For mitigating the uncertainty around the estimations, we have used an optimistic and pessimistic analysis.
The base case scenario showed that total direct costs and indirect costs attributed to the HIV/AIDS were US$7,946,530 and US$ 1,288,586 at the end of 2018. Moreover, the total cost is 8,785,116 US$.
Direct costs have formed approximately 85% of total costs. The policymakers and planners should consider that these costs are only related to diagnosed or registered infected populations. These costs will be raised dramatically with increasing the diagnosed patients.
在低收入和中等收入国家（LMICs），艾滋病毒/艾滋病是导致死亡和发病的主要原因。它可能会给卫生系统带来经济负担。伊朗艾滋病毒/艾滋病的流行情况尚无定论。因此，我们旨在估算伊朗艾滋病毒/艾滋病的疾病成本。
我们采用社会视角来计算伊朗艾滋病毒/艾滋病的直接和间接成本。我们使用了该国艾滋病毒/艾滋病监测系统2018年生成的年龄标准化患病率数据。该研究估算了伊朗成年人口假设队列（此处等同于监测系统中的所有登记病例）的直接和间接成本。为降低估算的不确定性，我们进行了乐观和悲观分析。
基础情景显示，2018年底，艾滋病毒/艾滋病的总直接成本和间接成本分别为7946530美元和1288586美元。此外，总成本为8785116美元。
直接成本约占总成本的85%。政策制定者和规划者应考虑到这些成本仅与已诊断或登记的感染人群相关。随着确诊患者数量的增加，这些成本将大幅上升。
